UCB Spinout Syndesi Brings New Approach To Dementia
Emerging Company Profile: Syndesi Therapeutics, a new biotech built upon research from UCB, aims to develop novel drugs for neurodegenerative conditions like Alzheimer's disease; the company has a stream of big name investors such as J&J Innovation and Novo Holdings.
You may also be interested in...
Johnson & Johnson Innovation has opened its first JLABS incubator in Europe, the 10th worldwide, with close links to its pharma R&D unit Janssen.
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.